Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer L Goldman

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
F1000Research|August 28, 2020
Pediatric SJS-TEN: Where are we now?Michele Ramien, Jennifer L Goldman
Journal of Clinical Pharmacology|February 12, 2016
Safety Concerns Surrounding Quinolone Use in ChildrenKarisma Patel, Jennifer L Goldman
Hospital Pediatrics|March 20, 2019
To Discharge or Not to Discharge on Outpatient Parenteral Antimicrobial Therapy: That Is the QuestionJessica L Markham, Jennifer L Goldman
Infectious Disease Clinics of North America|July 9, 2015
New Horizons for Pediatric Antibiotic StewardshipJennifer L Goldman, Jason G Newland
Pharmacoepidemiology and Drug Safety|June 6, 2018
Trimethoprim: The overlooked component of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactionsJennifer L Goldman, Leon van Haandel
Journal of the Pediatric Infectious Diseases Society|July 28, 2020
A Moving Target-Vancomycin Therapeutic MonitoringAlaina N Burns, Jennifer L Goldman
Clinical Pharmacology and Therapeutics|February 4, 2021
Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize ToxicityKevin J Downes, Jennifer L Goldman
Paediatric Drugs|July 8, 2021
Evaluating and Mitigating Risk of Acute Kidney Injury with the Combination of Vancomycin and Piperacillin-Tazobactam in ChildrenEmma M Tillman, Jennifer L Goldman
Pediatrics|July 22, 2015
Tip of the Iceberg: Understanding the Unintended Consequences of AntibioticsJennifer L Goldman, Mary Anne Jackson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2015
Editorial Commentary: Pediatric Acute Kidney Injury: Is the Addition of Gentamicin Worth the Risk?Sara Van Driest, Jennifer L Goldman
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
F1000Research|August 28, 2020
Pediatric SJS-TEN: Where are we now?Michele Ramien, Jennifer L Goldman
Journal of Clinical Pharmacology|February 12, 2016
Safety Concerns Surrounding Quinolone Use in ChildrenKarisma Patel, Jennifer L Goldman
Hospital Pediatrics|March 20, 2019
To Discharge or Not to Discharge on Outpatient Parenteral Antimicrobial Therapy: That Is the QuestionJessica L Markham, Jennifer L Goldman
Infectious Disease Clinics of North America|July 9, 2015
New Horizons for Pediatric Antibiotic StewardshipJennifer L Goldman, Jason G Newland
Pharmacoepidemiology and Drug Safety|June 6, 2018
Trimethoprim: The overlooked component of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactionsJennifer L Goldman, Leon van Haandel
Journal of the Pediatric Infectious Diseases Society|July 28, 2020
A Moving Target-Vancomycin Therapeutic MonitoringAlaina N Burns, Jennifer L Goldman
Clinical Pharmacology and Therapeutics|February 4, 2021
Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize ToxicityKevin J Downes, Jennifer L Goldman
Paediatric Drugs|July 8, 2021
Evaluating and Mitigating Risk of Acute Kidney Injury with the Combination of Vancomycin and Piperacillin-Tazobactam in ChildrenEmma M Tillman, Jennifer L Goldman
Pediatrics|July 22, 2015
Tip of the Iceberg: Understanding the Unintended Consequences of AntibioticsJennifer L Goldman, Mary Anne Jackson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2015
Editorial Commentary: Pediatric Acute Kidney Injury: Is the Addition of Gentamicin Worth the Risk?Sara Van Driest, Jennifer L Goldman
Pageof 10